Pathogenic Th17 (pTh17) cells drive inflammation and immune-pathology, but whether pTh17 cells are a Th17 cell subset whose generation is under specific molecular control remains unaddressed. We found that Ras p21 protein activator 3 (RASA3) was highly expressed by pTh17 cells relative to non-pTh17 cells and was required specifically for pTh17 generation in vitro and in vivo. Mice conditionally deficient for Rasa3 in T cells showed less pathology during experimental autoimmune encephalomyelitis. Rasa3-deficient T cells acquired a Th2 cell-biased program that dominantly trans-suppressed pTh17 cell generation via interleukin 4 production. The Th2 cell bias of Rasa3-deficient T cells was due to aberrantly elevated transcription factor IRF4 expression. RASA3 promoted proteasome-mediated IRF4 protein degradation by facilitating interaction of IRF4 with E3-ubiquitin ligase Cbl-b. Therefore, a RASA3-IRF4-Cbl-b pathway specifically directs pTh17 cell generation by balancing reciprocal Th17-Th2 cell programs. These findings indicate that a distinct molecular program directs pTh17 cell generation and reveals targets for treating pTh17 cell-related pathology and diseases.
In Brief
Pathogenic Th17 cells promote immune pathology, but how their generation is controlled remains largely unknown. Wu et al. reveal that RASA3 is essential for pathogenic Th17 cell generation but dispensable for non-pathogenic Th17 cell generation. RASA3 functions by repressing Th2 cell programs in pathogenic Th17 cells by fine-tuning IRF4 protein expression.
SUMMARY
Pathogenic Th17 (pTh17) cells drive inflammation and immune-pathology, but whether pTh17 cells are a Th17 cell subset whose generation is under specific molecular control remains unaddressed. We found that Ras p21 protein activator 3 (RASA3) was highly expressed by pTh17 cells relative to non-pTh17 cells and was required specifically for pTh17 generation in vitro and in vivo. Mice conditionally deficient for Rasa3 in T cells showed less pathology during experimental autoimmune encephalomyelitis. Rasa3-deficient T cells acquired a Th2 cell-biased program that dominantly trans-suppressed pTh17 cell generation via interleukin 4 production. The Th2 cell bias of Rasa3-deficient T cells was due to aberrantly elevated transcription factor IRF4 expression. RASA3 promoted proteasome-mediated IRF4 protein degradation by facilitating interaction of IRF4 with E3-ubiquitin ligase Cbl-b. Therefore, a RASA3-IRF4-Cbl-b pathway specifically directs pTh17 cell generation by balancing reciprocal Th17-Th2 cell programs. These findings indicate that a distinct molecular program directs pTh17 cell generation and reveals targets for treating pTh17 cell-related pathology and diseases.
INTRODUCTION

CD4
+ T cells differentiate into distinct effector T cell subsets to direct appropriate and effective responses to clear pathogens, eradicate tumors, and maintain immune homeostasis. Conversely, aberrant effector CD4 + cell function often leads to inflammatory and autoimmune diseases (Zhu et al., 2010) . Since the proposition of helper T (Th) 1 and Th2 cell paradigm in the 1980s (Mosmann et al., 1986) , additional Th cell types including Th17 (Harrington et al., 2005; Park et al., 2005) and regulatory T (Treg) cells (Sakaguchi, 2000) have been documented to function in distinct manners to control diverse and yet specific immune responses. In order to understand immune regulation during disease development and to treat immune-related diseases, we must address how the generation of Th cell subsets are controlled, a vital question that is under intensive investigation for decades. Different transcription factors master distinct Th cell subsets. T-bet, GATA3, RORgt (RAR-related orphan receptor gamma), and Foxp3 are central to Th1, Th2, Th17, and Treg cell generation and function, respectively (Fontenot et al., 2003; Hori et al., 2003; Ivanov et al., 2006; Szabo et al., 2000; Zheng and Flavell, 1997) . Nonetheless, the molecular programs controlling various Th cells are unsegregated but rather overlapping. The shared underlying molecular networks enable the intricate functional relationships, antagonistic or synergistic, between different Th cell subsets. It is the distinct and yet overlapping molecular programs that dictate the development and function of discrete Th cell subsets (O'Shea and Paul, 2010) .
Th17 cells that produce the signature cytokine interleukin 17A (IL-17A) have attracted great and increasing attention since its discovery, for its broad and diverse function in controlling immune responses during infection, inflammation, autoimmunity, and cancer (Dong, 2008; Korn et al., 2009; Patel and Kuchroo, 2015; Zou and Restifo, 2010) . Varying combinations of cytokine signaling activated by transforming growth factor-b1 (TGF-b1), IL-6, IL-1b, and IL-23 promotes RORgt expression and the subsequent Th17 cell development and function. Much of the current knowledge on the Th17 cell-determining molecular program is obtained by studying TGF-b1+IL-6-induced Th17 cells (Bettelli et al., 2006) . TGF-b1+IL-6-induced Th17 cells, although they can be pathogenic to certain degree, are largely non-pathogenic and produce signature immune regulatory cytokine IL-10 (McGeachy et al., 2007; Stumhofer et al., 2007) . Similarly, in vivo generated Th17 cells can be both pathogenic and non-pathogenic in a context-dependent manner (Ahern et al., 2010; Esplugues 
IL-17A et al., 2011). These observations suggest that pathogenic and non-pathogenic Th17 cells are functionally distinct and may be under specific molecular control (Bettelli et al., 2008; Peters et al., 2011) . To support such a notion, studies demonstrated that Th17 cells need additional IL-23 signal to gain pathogenic function (Ahern et al., 2010; Ghoreschi et al., 2010; Langrish et al., 2005; McGeachy et al., 2009) . Pathogenic Th17 and non-pathogenic Th17 cells have different gene expression profiles; pathogenic Th17 cells specifically express high levels of GM-CSF, IL-23R, and low levels of CD5L for pathogenicity (ElBehi et al., 2011; Lee et al., 2012; Wang et al., 2015) . In addition, cytokine combination IL-1b+IL-6+IL-23 is able to induce pathogenic Th17 cells (Chung et al., 2009; Ghoreschi et al., 2010; Lee et al., 2012; Wang et al., 2015) . Therefore, the acquisition of pathogenicity of Th17 cells requires special molecular programs. Nevertheless, the intriguing possibility remaining unaddressed and thus under intense pursuit is whether pathogenic and nonpathogenic Th17 cells can be categorized as distinct Th17 cell subtypes whose generation is controlled by discrete molecular programs. Available evidences suggest the contrary, however, because currently identified factors critical for Th17 cell differentiation including RORgt, BATF, and IRF4 (interferon regulatory factor 4) are indistinguishably required for the generation of both pathogenic and non-pathogenic Th17 cells (Br€ ustle et al., 2007; Ivanov et al., 2006; Schraml et al., 2009) .
Here, we revealed that Ras p21 protein activator 3 (RASA3), a GTPase activating protein of GAP1 sub-family (Schurmans et al., 2015) , is specifically required for the generation of pathogenic Th17 cells. RASA3 does so by balancing the reciprocal molecular programs of pTh17-Th2 cells via RASA3-IRF4-Cbl-b (Cbl proto-oncogene-B) pathway. The study provides evidence to support the notion that pathogenic and non-pathogenic Th17 cells are distinct Th17 cell subtypes generated through discrete molecular programs. In addition, it reveals RASA3-IRF4-Cbl-b a critical molecular hub to direct pathogenic Th17 cell generation; targeting this hub may benefit the treatment of Th17 cell-related pathology and diseases.
RESULTS
RASA3
Is Required Specifically for Pathogenic Th17 (pTh17) Cell Generation In Vitro To identify the molecule(s) that determine pTh17 cell generation, we compared the gene expression between IL-6+IL-1b+IL-23-polarized pTh17 cells and IL-6+TGF-b1-polarized Th17 cells that are much less pathogenic. We found that RASA3, a factor previously identified as being highly expressed by Th17 cells (Lee et al., 2012) , was preferentially upregulated at both mRNA ( Figure 1A ) and protein ( Figure 1B ) levels during pTh17 cell differentiation, suggesting its potential role in pTh17 cells. RASA3 has been well studied for platelet function (Stefanini et al., 2015) . Its role in T cells, however, remains unknown.
To investigate RASA3 function in T cells, we generated Rasa3 Figure S1A ). The T cell homeostasis in the periphery (Figures S1B-S1E) and intestines ( Figure S1F ) remained unperturbed in the absence of RASA3. The normal phenotype of RASA3-deficient T cells under steady state allowed us to investigate how RASA3 controls Th17 cell differentiation.
When activated in the presence of IL-6+TGF-b1, RASA3-deficient and -sufficient CD4 + T cells generated similar percentages of IL-17A + cells ( Figure 1C ). In addition, compared to RASA3-sufficient CD4 + T cells, RASA3-deficient CD4 + T cells expressed largely normal levels of Il17a, Rorc, Il23r, and Csf2, but higher levels of Il10 and Cd5l ( Figure 1D ). Nonetheless, when activated in the presence of IL-1b+IL-6+IL-23, RASA3-deficient cells generated much lower percentages of IL-17A + cells than RASA3-sufficent cells ( Figure 1E ), with impaired expression of pTh17 cell-related genes, including Il17a, Rorc, Il23r, and Csf2. The expression of Il10 and Cd5l, signature genes for non-pathogenic Th17 cells, was, however, elevated in RASA3-deficient pTh17 cells ( Figure 1F ). The differential requirement of RASA3 for pTh17 cell generation was not due to a difference in T cell proliferation or survival. RASA3-deficient and -sufficient CD4 + T cells proliferated (Figure 1G) and survived ( Figure 1H ) similarly when activated in the presence of IL-1b+IL-6+IL-23 or IL-6+TGF-b1. In addition, the Th1 and Th2 cell differentiation appeared normal in the absence of RASA3 ( Figure S1G ). These findings therefore suggest that the generation of pTh17 cells specifically requires RASA3.
RASA3 Is Required for pTh17 Cell Generation and Immune Pathology during Experimental Autoimmune Encephalomyelitis (EAE)
The generation of pTh17 cells is paramount to induce tissue immune pathology for the development of autoimmune diseases See also Figure S1 .
including experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis. The aforementioned findings prompted us to investigate whether RASA3 is required for pTh17 cell generation and immune pathology in vivo during myelin oligodendrocyte glycoprotein (MOG)-and complete Freund's adjuvant (CFA)-elicited EAE. We found that the incidence of EAE disease was lower and the disease onset was delayed in Rasa3 flox/flox Cd4Cre mice when compared to Rasa3 flox/+ Cd4Cre mice ( Figure 2A ). In addition, the EAE was (legend continued on next page) although the numbers of spinal cord infiltrating CD4 + cells were similar between these two types of mice ( Figure S2A ). On the contrary, the fractions of IL-10 + cells were increased in spinal cord-infiltrating CD4 + cells in Rasa3 flox/flox Cd4Cre mice (Figure 2F) , although Foxp3 + Treg cell population remained unaffected ( Figure S2B ). Consistently, spinal cord-infiltrating RASA3-deficient CD4 + T cells expressed decreased levels of pTh17-related genes including Rorc, Il17a, Il23r, and Csf2, but increased level of non-pathogenic Th17 cell-related gene Il10 ( Figure 2G ). These findings indicate that RASA3 is required for the generation of pTh17 cells to cause tissue immune pathology and subsequent autoimmunity.
Loss of RASA3 Leads to a Dominant trans-Repression of pTh17 Cell Generation via Soluble Factors of Th2 Cell Bias
To reveal the mechanisms underlying the critical role for RASA3 in pTh17 cell generation, we first addressed whether RASA3 deletion led to a dominant or recessive effect to limit pTh17 generation by mixing RASA3-deficient and -sufficient T cells during pTh17 cell differentiation. We found that, while RASA3-deficient cells remained defective in producing IL-17A, co-existing wild-type cells also became unable to produce IL-17A ( Figure 3A ), suggesting that RASA3 deletion led to a dominant, trans-repression of pTh17 cell generation. Such an effect was likely due to soluble factor(s) produced by RASA3-deficient cells, as RASA3-deficient pTh17 cell conditioned medium inhibited pTh17 differentiation of wildtype cells ( Figure 3B ) and their expression of pTh17-cellrelated genes ( Figure 3C ). We therefore sought to identify how the expression of genes, especially the cytokines, were altered in RASA3-deficient cells during pTh17 cell differentiation by using genome-wide RNAseq analysis. Compared to RASA3-sufficient T cells, RASA3-deficient T cells expressed less Th17 cell-related genes, including Il17a and Rorc, during pTh17 cell differentiation (Figure S3A) . However, we found that Th2, but not Th1, cytokines and related genes were aberrantly upregulated in RASA3-deficient cells as early as 6 hr post activation under pTh17 cell polarizing condition ( Figures 3D-3F and S3B) . Consistently, the percentages of IL-4 + and IL-10 + cells increased in the absence of RASA3 during pTh17 cell differentiation in vitro ( Figure 3G ). Furthermore, spinal-cord-infiltrating RASA3-deficient CD4 + T cells expressed increased levels of Th2 cell-related genes during EAE ( Figure S3C ). The aforementioned findings therefore suggest that RASA3 is required to restrict Th2 cell-related program in developing pTh17 cells.
Defective pTh17 Cell Generation in the Absence of RASA3 Is due to Aberrant IL-4 Expression The findings from the genome-wide RNA-seq analysis suggested that aberrantly upregulated IL-4 and/or IL-10 may account for defective pTh17 cell generation in the absence of RASA3. By using antibodies against IL-4 and IL-10, we found that neutralizing IL-4 ( Figure 4A ), but not IL-10 ( Figure S4A ), restored the capacity of RASA3-deficient CD4 + T cell to differentiate into pTh17 cells in vitro. In addition, neutralizing IL-4 (Figure 4B) but not IL-10 ( Figure S4B ) abolished the ability of RASA3-deficient CD4 + T cells to dominantly trans-repress pTh17 cell generation of wild-type CD4 + T cells in vitro. Elevated IL-10 production by RASA3-deficient CD4 + T cells depended on IL-4, because IL-4 neutralization hampered IL-10 upregulation in these cells ( Figure 4C ). Deletion of IL-4 in RASA3-deficient cells not only restored pTh17 cell generation and the expression of pTh17-cell-related genes but also reduced IL-10 production and the Th2 cell-bias program of RASA3-deficient CD4 + T cells in vitro (Figures 4D and 4E) .
IL-4 was critical to inhibit pTh17 cell generation in the absence of RASA3 during EAE development in vivo. IL-4 + cells were increased in the spinal cords of Rasa3 flox/flox Cd4Cre mice during EAE development ( Figure S4C ), suggesting a role for IL-4 to reduce EAE disease in these mice (Figure 2 ). Antibody-mediated neutralization of IL-4 largely restored EAE development in Rasa3 flox/flox Cd4Cre mice ( Figures S4D-S4F ) and pTh17 cell generation ( Figure S4G ), and normalized IL-10 production in the spinal cord ( Figure S4H ). Deletion of IL-4 restored EAE development of Rasa3 flox/flox Cd4Cre mice ( Figures 4F and 4G ). The defective pTh17 cell generation, aberrant IL-10 production, and Th2 cell bias observed in the spinal-cord-infiltrating T cells in Rasa3 flox/flox Cd4Cre mice were corrected when IL-4 was deleted ( Figures 4H, 4I , and S4I). These findings suggest that RASA3 is critical to control the reciprocal pTh17 and Th2 cell programs. Lack of RASA3 causes CD4 + T cell to deviate from pTh17 cell and bias toward Th2 cell function, which in turn restricts pTh17 cell generation in an IL-4-dependent manner.
RASA3 Controls IL-4 Expression during pTh17 Cell Generation via Interferon Regulatory Factor 4 (IRF4)
Aforementioned findings promoted us to determine the molecular mechanisms through which RASA3 regulates IL-4 expression. 
Il10
Relative mRNA amounts GATA3, IRF4, c-Maf, and STAT6-phosphrylation are central to Th2 cell program (Ho et al., 1998; Lohoff et al., 2002; Rengarajan et al., 2002; Zheng and Flavell, 1997) and are found upregulated in RASA3-deficient CD4 + T cells during pTh17 cell generation ( Figures 5A and S5A) . Nonetheless, because IL-4 promotes Th2 cell programs through feed-forward mechanisms, it is possible that some of the observed upregulation was a ''result'' rather than the ''cause'' of the aberrant IL-4 upregulation in the RASA3-deficient pTh17 cells. To distinguish the two possibilities, we abrogated IL-4 by using either neutralizing antibody or genetic deletion. The upregulation of IRF4, but not that of GATA3, c-Maf, and STAT6-phosphorylation, in RASA3-deficient CD4 + T cells was independent of IL-4 ( Figures 5B, 5C , and S5B), suggesting that IRF4 upregulation caused IL-4 increase in RASA3-deficient cells. Indeed, short hairpin RNA (shRNA)-mediated IRF4 knockdown in RASA3-deficient cells ( Figure 5D ) normalized IL-4 expression and Th2 cell-related program ( Figure 5E ), and restored pTh17 cell generation ( Figure 5F ) and pTh17-cell-related programs ( Figure 5G ). In addition, we found that RASA3 and IRF4 expression were reciprocally regulated during pTh17 and Th2 cell generation ( Figure S5C ), and that ectopically expressed IRF4 suppressed pTh17-related program but promoted Th2-related program during pTh17 cell generation specifically ( Figure S5D ). Aforementioned findings suggest that RASA3-IRF4 axis balances pTh17 cell-and Th2 cell-related program to specifically direct pTh17 cell generation.
RASA3 Bridges the Interaction between Cbl
Protooncogene-b (Cbl-b) and IRF4 for IRF4 Degradation Because we found that RASA3 balanced pTh17-Th2 cell programs via IRF4, we further investigated how RASA3 regulates IRF4 expression. In the absence of RASA3, IRF4 mRNA expression did not increase during pTh17 cell generation ( Figure S6A ), suggesting that IRF4 upregulation occurred via a post-transcriptional mechanism. Indeed, IRF4 protein stability greatly enhanced in RASA3-deficient pTh17 cells ( Figure 6A ). Proteasome-dependent protein degradation was found important to control IRF4 protein stability, as the inhibition of proteasome activity increased IRF4 expression in the wild-type cells to a similar level as in RASA3-deficient cells ( Figure 6B ). RASA3 controls IRF4 protein stability likely through a direct mechanism, because by combining immunoprecipitation and unbiased mass-spectrometry (IP-MS) analysis, we found that RASA3 bound to IRF4, but not GATA3 or c-Maf, during pTh17 cell differentiation (Figures S6B and S6C) . The IP-MS approach also revealed that RASA3 interacted with E3-ubiquitin ligases, among which Cbl proto-oncogene-b (Cbl-b) is known to suppress Th2 cell differentiation (Figures S6B and S6D ; Qiao et al., 2014) . RASA3 indeed interacted with IRF4 and Cbl-b during pTh17 cell generation, detected by endogenous co-immunoprecipitation assays (Figures 6C and S6E ). In addition, we found that IRF4 and Cbl-b interact with each other and such an interaction requires RASA3 because the interaction between IRF4 and Cbl-b became much weaker upon RASA3 deletion ( Figure 6D ).
These findings suggest that RASA3 facilitates Cbl-b to interact with IRF4 to degrade IRF4 via poly-ubiquitination. In 293T cells where RASA3 is barely expressed, ectopically expressed IRF4 and Cbl-b did not interact strongly until RASA3 was introduced ( Figure S6F ). RASA3 expression promoted IRF4 protein poly-ubiquitination ( Figure 6E ) and proteasome-mediated degradation in a Cbl-b-dependent manner (Figures 6E and S6G) . Therefore, RASA3 is required for Cbl-b to interact with IRF4 to mediate the poly-ubiquitination and degradation of IRF4. These results indicate that RASA3 bridges the interaction of Cbl-b to IRF4 to promote IRF4 protein degradation.
Collectively, aforementioned findings reveal an essential role for RASA3 in directing pTh17 cell generation by counterbalancing Th2 cell-related program through restraining IRF4 function. RASA3 does so mechanistically by mediating the interactions between E3 ubiquitin Ligase Cbl-b and IRF4 to promote IRF4 protein degradation ( Figure S6H ).
DISCUSSION
Since the first description of IL-17A-producing Th17 cells, such a cell type has attracted great attention for its vital role in promoting immune response and causing immune pathology in myriad immune-related diseases (Dong, 2008; Korn et al., 2009; Patel and Kuchroo, 2015; Zou and Restifo, 2010) . Subsequent studies, See also Figure S4 .
however, reveal that IL-17A-producing cells may also possess immune-regulatory function (Esplugues et al., 2011; McGeachy et al., 2007; Stumhofer et al., 2007) , suggesting that Th17 cells' function is more diverse and context dependent than previously thought. Indeed, different cytokine combinations endow Th17 cells with pathogenic (IL-1b+IL-6+IL-23) or non-pathogenic (TGF-b+IL-6) functions. In addition, the molecular programs of pathogenic and non-pathogenic Th17 cell are quite different (Gaffen et al., 2014; Lee et al., 2012) . These findings beg the question of whether pathogenic and non-pathogenic Th17 cells can be classified as distinct Th17 cell subtypes or mere functional adaptations of Th17 cells to the environmental cues. Previous available evidence supports the latter, because critical factors including IL-23-IL-23R and CD5L contribute to the pathogenicity, but not the generation, of Th17 cells (Langrish et al., 2005; Stritesky et al., 2008; Wang et al., 2015) . The current study offered the evidence to support the notion that unique molecular programs including RASA3 indeed exist to diverge (E) qRT-PCR assays to determine mRNA levels of Th2 cell-related genes expressed in cells as described in (D). n = 3 samples from 3 independent experiments; *p < 0.05, **p < 0.01, ***p < 0.001 per two-sided t test; centers indicate the mean values.
(F) Flow cytometry of IL-17A produced by cells as described in (D). n = 3 samples from 3 independent experiments, *p < 0.05 per two-sided t test; centers indicate the mean values.
(G) qRT-PCR assays to determine mRNA levels of Th17 cell-related genes expressed in cells as described in (D). n = 3 samples from 3 independent experiments; *p < 0.05, ***p < 0.001, per two-sided t test; centers indicate the mean values. See also Figure S5 .
pathogenic-Th17 cell generation from non-pathogenic-Th17 cell generation. It is therefore likely that, to achieve the functional diversification of Th17 cells, both lineage development and functional adaptation are involved.
Despite Th cell subsets are functionally distinct and engage cell-type-specific molecular networks, they do share common molecular modules to permit mutual regulation, whether it be antagonism or synergism. In particular, TGF-b1+IL-6-polarized non-pathogenic Th17 cells share genetic and epigenetic features with Th1, Th2, and Treg cells (O'Shea and Paul, 2010; Zhou et al., 2009) . It is thought to be the molecular underpinning of functional malleability of Th17 cells toward Th1, Th2, and Treg cells (Bending et al., 2009; Gagliani et al., 2015; Harbour et al., 2015; Panzer et al., 2012; Zhou et al., 2009) . Because pathogenic and non-pathogenic Th17 cells have been distinguished only in recent years, whether pathogenic Th17 cells, like non-pathogenic Th17 cells, possess such a diverse malleability with broadly shared molecular modules of other Th cell subsets is a question of interest. Available evidence suggests that pathogenic Th17 cells adopt Th1 signatures rather readily. In fact, T-bet, a Th1 master regulator, has been associated with pathogenic Th17 cells , suggesting that pathogenic Th17 and Th1 cell generation are compatible. Conversely, pathogenic Th17 and Th2 cell generation appears reciprocal (Choy et al., 2015; Harrington et al., 2005) . Our finding that RASA3 is required for pathogenic Th17 cell generation by restraining Th2 cell program highlights an antagonism between pathogenic Th17 and Th2 cell programs and thus provides much needed mechanistic insights for above-mentioned observations. It is therefore plausible that, compared to non-pathogenic Th17 cells, the functional malleability of pathogenic Th17 cells is more limited. A question warrants further investigation. The mutual regulation between pathogenic Th17 and Th2-related programs does not occur by chance, because IRF4, a classical Th2 cell-promoting factor (Lohoff et al., 2002; Rengarajan et al., 2002) , is also essential for Th17 cell generation (Br€ ustle et al., 2007; Ciofani et al., 2012) . These observations seemingly contradict our observation that RASA3 controls the reciprocal programs of pathogenic Th17 and Th2 cells through IRF4. Nonetheless, our findings suggest that the levels of IRF4 expression appeared to be critical: high levels of IRF4 expression suppressed and medium levels of IRF4 expression enhanced the pathogenic-Th17 cell generation of RASA3-deficent CD4 + T cells. Yet, low levels of IRF4 expression led to a reduction of pathogenic Th17 cell generation of these cells. These findings suggest that IRF4 controls pathogenic Th17 cell program in a dose-dependent manner. Medium levels of IRF4 expression is required to promote pathogenic Th17 cell program and yet high levels of IRF4 expression conversely restrict pathologic Th17 cell programs by favoring Th2 cell program. Therefore, IRF4 serves as a sensitive and critical ''rheostat'' to control pathogenic Th17 cell generation and the reciprocal programs of pathogenic Th17 and Th2 cells. These findings echo accumulating evidence to suggest that an important way for IRF4 to control diverse functions in various immune cell subsets is through its expression levels (Krishnamoorthy et al., 2017; Man et al., 2013; Ochiai et al., 2013; Yao et al., 2013) . The mechanisms underlying such a dose-dependent IRF4 function has been attributed to its ability to be recruited toward target sites to control gene expression and gene locus accessibility in order to program different cell fates and functions. The greater IRF4 abundance permits its binding to low-affinity binding sites in the genome. A large number of promoters and enhancers involved in gene regulation are regulated by IRF4 in a dosedependent manner in a cell type-specific fashion (Krishnamoorthy et al., 2017; Ochiai et al., 2013; Yao et al., 2013) . It is therefore predicted that different levels of IRF4 expression observed in pathogenic and non-pathogenic Th17 and Th2 cells lead to discrete IRF4 binding patterns in the genome. What genetic loci are differentially bound by IRF4 in a dose-dependent manner and how they contribute to pathogenic and non-pathogenic Th17 and Th2 cell generation are questions warranting future investigation. In addition, in order to target pathogenic Th17 cell function to treat related immune diseases, identifying factors besides RASA3 in fine-tuning IRF4 expression would be of interest.
IRF4 plays multi-faceted roles in controlling diverse T cell functions including Th2 and Th17 cell generation (Huber and Lohoff, 2014) . We now discovered that IRF4 balances the pathogenic Th17 and Th2 cell programs in a RASA3-dependent manner for pathogenic Th17 cell generation, and that RASA3 does so through a previously unappreciated mechanism by protein degradation. Proteomic approaches revealed that RASA3 and IRF4 belong to protein complex containing E3-ubiquitin ligases including Cbl-b. The current study focused on elucidating the role for Cbl-b, due to its known role in controlling Th2 cell differentiation, in mediating RASA3-dependent IRF4 poly-ubiquitination, and in degradation. Nonetheless, several other E3-ubiquitin ligases, including Cbl, Prpf19, and Trim21, also belong to RASA3-IRF4 interactome and may contribute to IRF4 regulation. In addition, because the above-mentioned E3-ubiquitin ligases may have diverse targets, it warrants further investigation whether and how factors other than IRF4 contribute to RASAdirected pathogenic Th17 cell differentiation. Current findings support the notion that protein degradation is critical to control Th17 cell function, which is confirmed by increasing evidence (Kathania et al., 2016; Rutz et al., 2015; Zhang et al., 2017) . Such a notion remains an important and yet poorly addressed proposition that warrants further investigation to reveal ''druggable'' ubiquitin ligases for treating Th17 cell-related pathology and diseases.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
collision-activated dissociation-MS/MS was used to dissociate peptides at a normalized collision energy (NCE) of 26 eV. Dynamic exclusion with 20.0 s was enabled. Then the mass spectra were processed, and peptide identification was performed using the Andromeda search engine found in MaxQuant software version 1.6.0.16 (Max Planck Institute, Germany) against the UniProt mouse protein sequence database (UP000000589). Peptides were identified with a target-decoy approach using a combined database consisting of reverse protein sequences of the database. Up to two missed cleavages was allowed. Peptide identifications are reported by filtering of reverse and contaminant entries and assigning to their leading razor protein. Peptide inference and proteins identification were filtered to maximum 1% and 5% false discovery rate (FDR), respectively. Data processing and statistical analysis were performed on Perseus (Version 1.6.0.7). A two samples t test statistics was used with a p value < 0.05 to report statistically significant expression.
Ectopic gene expression and shRNA-mediated gene knock down For ectopic gene expression, full-length cDNA encoding IRF4, RASA3 and Cbl-b (Transomics) were cloned into pCMV-Flag vector, MSCV-IRES-EGFP (MIG) vector or MSCV-IRES-Thy1.1 (MIT) vectors. For shRNA-mediated gene knockdown, lenti-viral shRNA constructs carrying puromycin resistance genes (MISSION shRNA library, Sigma) were purchased from shRNA core facility of UNC Chapel Hill. Scrambled shRNA constructs (pLKO.1-scramble shRNA control) carrying puromycin resistance gene was obtained from Addgene.
Lentiviruses and retroviruses were prepared by transfecting HEK293T cells. Activated T cells were spin inoculated with recombinant viruses by centrifuging at 1,500 x g for 2 hours at 30 C with 10mM HEPES and 8 mg/mL polybrene. Antibiotic selection was performed, when applicable, by adding 2 mg/mL puromycin in the culture medium. The transduced cells were then identified based on puromycin resistance or Thy1.1 positive.
Lamina propria leukocytes isolation
Small or large intestine was mechanically dissected and flushed with ice-cold PBS. The intestines were cut into 8 pieces and incubated in the presence of 1mM DTT and 5mM EDTA at 37 C for 30 min. The digested pieces were passed through a 100 mm cell strainer. The cell suspension was discarded. The remaining pieces were cut into 1mm pieces and further digested in RPMI 1640 medium with collagenase D (1mg/mL collagenase D, Roche), DNase I (100 mg/ ml, Sigma), Liberase TL (0.2mg/mL, Roche) and 10% FBS at 37 C for 1h. The LPL were isolated by centrifuging at 2000rpm for 20 min with 40% and 80% discontinuous Percoll density gradient (Sigma). Isolated LPL were then subjected to subsequent analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Two-tailed/sided Student's t test was used to compare two groups of samples. Mann-Whitney test was used to compare multiple groups of samples in EAE experiments. p < 0.05 (confidence interval of 95%) was considered statistically significant. In the figures, *, ** and *** were used to indicate p < 0.05, p < 0.01 and p < 0.001 respectively. All results shown are mean ± SD unless stated otherwise.
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